Evidence map›Paper›PMID 34867976›Full record

ArticleFrontiers in immunology2021

Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas.

Wentao Fang, Chia-Hsin Wu, Qiang-Ling Sun, Zhi-Tao Gu, Lei Zhu, Teng Mao, Xue-Fei Zhang, Ning Xu, Tzu-Pin Lu, Mong-Hsun Tsai and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Wentao FangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Chia-Hsin WuGraduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
Qiang-Ling SunDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Zhi-Tao GuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Lei ZhuDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Teng MaoDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Xue-Fei ZhangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Ning XuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Tzu-Pin LuBioinformatics and Biostatistics Core, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Mong-Hsun TsaiBioinformatics and Biostatistics Core, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Li-Han ChenInstitute of Fisheries Science, National Taiwan University, Taipei, Taiwan.
Liang-Chuan LaiBioinformatics and Biostatistics Core, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Eric Y ChuangGraduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
National Taiwan University · TWShanghai Chest Hospital · CNShanghai Jiao Tong University · CNChina Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymic carcinoma (TC) is the most aggressive thymic epithelial neoplasm. TC patients with microsatellite instability, whole-genome doubling, or alternative tumor-specific antigens from gene fusion are most likely to benefit from immunotherapies. However, due to the rarity of this disease, how to prioritize the putative biomarkers and what constitutes an optimal treatment regimen remains largely unknown. Therefore, we integrated genomic and transcriptomic analyses from TC patients and revealed that frameshift indels in

Indexed as

AdultAgedAntigens, NeoplasmCarcinogenesisFemaleGenomicsHumansImmunotherapyMaleMiddle AgedThymomaThymus NeoplasmsTranscriptomeAntigens, Neoplasmdriver alterationgene fusionimmune checkpoint inhibitor (ICI)immunotherapyneoantigenRNA sequencing (RNAseq)thymic carcinoma (TC)whole-exome sequencing (WES)

Identifiers

PMID34867976
PMCPMC8635231
OpenAlexW3214251490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.